vimarsana.com

Page 10 - தொழில்நுட்பம் தேர்ந்தெடுக்கவும் துறை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Diversify Your Portfolio And Hedge Your Bets With April s Top ETFs

Diversify Your Portfolio And Hedge Your Bets With April s Top ETFs
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.

Tech Sector Boosted Dividends to Start 2021

Tech Sector Boosted Dividends to Start 2021 In the first quarter of 2021, companies were 14 times more likely to have positively raised or initiated a dividend than negatively cut or suspended dividend payments. This was nearly triple the ratio from a year earlier. Dividend growth returned in early 2021 as the economic impact of the pandemic began to ease. In the first three months of 2021, 906 U.S. companies either raised or initiated a dividend according to S&P Dow Jones Indices, up 24% from a year earlier as COVID-19 fears were first heating up. Meanwhile, the number of companies that either cut or suspended dividends fell by more than 50% to just 64. The 14-to-1 positive/negative ratio was much higher than way before the pandemic, with the 7-to-1 ratio in 2019 the recent high-water mark in the last six years. Among S&P 500 companies, there was just one dividend suspension in the first quarter of 2021, down from 10 a year earlier and 31 in the second quarter of 2021.

3 Top Growth Stocks to Buy That Were Down More Than 15% in March

Roku (NASDAQ:ROKU). Here s a closer look at how badly they ve done of late and why they re still worth investing in right now.  Image source: Getty Images. 1. Moderna Shares of Moderna slipped to less than $120 late in March a nearly three-month low for the healthcare stock. It s possible that the company s year-end results, which Moderna released on Feb. 25, played in a role in the stock s recent activity. For the fourth quarter (ended Dec. 31, 2020), the company generated $570.7 million in revenue, which was more than 40 times the $14.1 million it posted in the prior-year period. But despite the boost in grant revenue and Moderna now reporting product sales, its net loss of $272.5 million was more than double the $123.3 million loss it incurred a year ago. 

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.